Prognostic relevance of C-terminal Mdm2 detection is enhanced by p53 positivity in soft tissue sarcomas

Diagnostic Molecular Pathology

Volumn 6, Issue 5, 1997, Pages 249-254

  Würl, Peter ^a   Meye, Axel ^a   Berger, Dieter ^a   Bache, Matthias ^a   Lautenschläger, Christine ^a   Schmidt, Hannelore ^a   Kalthoff, Holger ^b   Rath, Friedrich Wilhelm ^a   Taubert, Helge ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Immunohistochemistry; Mdm2; p53; Prognosis; Soft tissue sarcoma

Indexed keywords

PROTEIN P53;

ADOLESCENT; ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CANCER STAGING; CARBOXY TERMINAL SEQUENCE; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; SOFT TISSUE SARCOMA; TUMOR BIOPSY; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SARCOMA; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0344906097     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019606-199710000-00001     Document Type: Article

References (47)

1. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 1993;12:461-8.
2. Barak Y, Oren M. Enhanced binding of a 95 kD protein to p53 in cells undergoing p53 mediated growth arrest. EMBO J 1992;11: 2115-21.
3. Böttger V, Böttger A, Howard SF, et al. Identification of novel mdm2 binding peptides by phage display. Oncogene 1996;13: 2141-7.
4. Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993;13:4107-14.
5. Chen J, Wu X, Lin J, Levine AJ. mdm2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 1996;16:2445-52.
6. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994;54:794-9.
7. Dei Tos AP, Doglioni C, Piccinin S, et al. Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma. J Pathol 1997; 181:8-13.
8. Dei Tos AP, Maestro R, Doglioni C, et al. Tumor suppressor genes and related molecules in leiomyosarcoma. Am J Pathol 1996;148: 1037-45.
9. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 1991;10:1565-9.
10. Finlay CA. The mdm2 oncogene can overcome wild type p53 suppression of transformed cell growth. Mol Cell Biol 1993;13: 301-6.
11. Florenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O, Fodstad O. MDM2 gene amplification and transcript levels in human sarcomas: relationship to tp53 gene status. J Natl Cancer Inst 1994;86:1297-302.
12. Gorgoulis VG, Zoumpourlis V, Rassidakis GZ, et al. A molecular and immunohistochemical study of the mdm2 isoforms and p53 gene product in bronchiogenic carcinoma. J Pathol 1996;180:129-37.
13. Hall P, Lane DP. P53 in tumor pathology: can we trust immunohistochemistry? - Revisited! J Pathol 1994;172:1-4.
14. Kussie PH, Gorina S, Marechal V, et al. Structure of the mdm2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996;274:948-53.
15. Ladanyi M, Cha C, Lewis R, Jahnwar SC, Huvos AG, Healey JA. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 1993;53:16-8.
16. Ladanyi M, Lewis R, Jahnwar SC, Gerald W, Huvos AG, Healey JH. MDM2 and CDK4 gene amplification in Ewing's sarcoma. J Pathol 1995;175:211-7.
17. Landers JE, Haines DS, Straus JF, George DL. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 1994;9:2745-50.
18. Leach FS, Tokino T, Meltzer P, et al. p53 mutation and mdm2 amplification in human soft tissue sarcomas. Cancer Res 1993;53: 2231-4.
19. Lianes P, Orlow I, Zhang ZF, et al. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 1994;86:1325-30.
20. Lin J, Chen J, Elenbaas B, Levine AJ. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein Genes Dev 1994;8:1235-46.
21. Martin K, Trouche D, Hagemeier C, Sorensen TS, La Thangue NB, Kouzarides T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 1995;375:691-4.
22. Meddeb M, Valent A, Danglot G, et al. MDM2 amplification in a primary alveolar rhabdomyosarcoma displaying a t(2;13)(q35;q14). Cytogenet Cell Genet 1996;73:325-30.
23. Meltzer PS, Jankowski SA, Dal Cin P, Sandberg AA, Paz IB, Coccia MA. Identification and cloning of a novel amplified DNA sequence in human malignant fibrous histiocytoma derived from a region of chromosome 12 frequently rearranged in soft tissue tumors. Cell Growth Differ 1991;2:495-501.
24. Momand J, Zambetti GP. Analysis of the proportion of p53 bound to mdm2 in cells with defined growth characteristics. Oncogene 1996;12:2279-89.
25. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell 1992;69:1237-45.
26. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-3.
27. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein mdm2 conceals the activation domain of tumour suppressor p53. Nature 1993;362:857-60.
28. Olson DC, Marechal V, Momand J, Chen J, Romocki C, Levine AJ. Identification and characterisation of multiple mdm2 proteins and mdm2-p53 protein complexes. Oncogene 1993;8:2353-60.
29. Otto A, Deppert W. Upregulation of mdm2 expression in meth a tumor cells tolerating wild type p53. Oncogene 1993;8:2591-603.
30. Pacinda SJ, Ledet SC, Gondo MM, et al. p53 and MDM2 immunostaining in pulmonary blastomas and bronchiogenic carcinomas. Hum Pathol 1996;27:542-6.
31. Patterson H, Bares D, Gill S, et al. Amplification and over-expression of the mdm2 gene in human soft tissue tumours. Sarcoma 1997;1:17-22.
32. Picksley SM, Vojtesk B, Sparks A, Lane DP. Immunochemical analysis of the interaction of p53 with MDM2: fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 1994;9:2523-9.
33. Pilotti S, Della Torre G, Lavarino C, et al. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenic mechanisms. J Pathol 1997;181:14-24.
34. Pollock RE, Lang A, El-Naggar AK, Radinsky R, Hung MC. Enhanced mdm2 oncoprotein expression in soft tissue sarcoma: several possible mechanisms. Sarcoma 1997;1:23-9.
35. Reid AH, Tsai MM, Venzon DJ, Wright CE, Lack EE, O'Leary TJ. MDM2 amplification, p53 mutation, and accumulation of the p53 gene product in malignant fibrous histiocytoma. Diagn Mol Pathol 1996;5:65-73.
36. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nature Med 1996;2:912-7.
37. Stephen CW, Helminen P, Lane DP. Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insight into antibody-peptide interactions. J Mol Biol 1995;248:58-78.
38. Taubert H, Meye A, Würl P. Prognosis is correlated with p53 mutation type for soft tissue sarcoma patients. Cancer Res 1996; 56:4134-6.
39. Taubert H, Würl P, Meye A, et al. Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma. Cancer 1995;76:1187-96.
40. Ungar S, Van de Meeren A, Tammilehto L, Linnainmaa K, Mattson K, Gerwin BI. High levels of mdm2 are not correlated with the presence of wild-type p53 in human malignant mesothelioma cell lines. Br J Cancer 1996;74:1534-40.
41. Van Unnik JAM, Coindre JM, Contesso G, et al. Grading of soft tissue sarcomas: experience of the EORTC soft tissue sarcoma group. In: Ryan JR, Baker LO, eds. Recent concepts in sarcoma treatment. Dordrecht, The Netherlands: Kluwer Academic, 1988: 7-13.
42. Villuendas R, Pezzella F, Gatter K, et al. p21WAF1/CIP1 and mdm2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, mdm2-, p21-immunophenotype associated with missense p53 mutations. J Pathol 1997;181:51-61.
43. Waber PG, Chen J, Nisen PD. Infrequency of mdm2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas. Cancer Res 1993; 53:6028-30.
44. Wu X, Bayle H, Olson D, Levine AJ. The p53-mdm2 autoregulatory feedback loop. Genes Dev 1993;7:1126-32.
45. Würl P, Taubert H, Bache M, et al. Frequent occurrence of p53 mutations in rhabdomyosarcoma and leiomyosarcoma, but not in fibrosarcoma and malignant neural tumors. Int J Cancer 1996;69: 317-23.
46. Würl P, Taubert H, Meye A, et al. Prognostic value of immunohistochemistry for p53 in primary soft tissue sarcomas: a multivariate analysis of five antibodies. J Cancer Res Clin Oncol 1997; 123:502-8.
47. Xiao ZX, Chen J, Levine AJ, et al. Interaction between the retinoblastoma protein and the oncoprotein mdm2. Nature 1995;375: 694-8.